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Recognition of foreign antigens byT lymphocytes involves trimolecular interac-
tions between : (a) the receptors present on T cells (TCRs) ; (b) antigenic peptides ;
and (c) the class I or class II MHC molecules on APCs . Recent experiments that
demonstrate physical binding of peptides to murine class IIMHC molecules (1, 2),
analysis of the structural and functional properties of transfectedMHC class 2 gene
products (reviewed in references 3, 4), and the solution of the crystal structure of
a human class I MHC molecule (5) have led to a clearer picture of the nature of
these interactions. The putative peptide binding site onMHC molecules isbounded
by two a-helical regions . Most allele-specific residues lie on or between these helices,
and potentially affect both the shape of the binding site and epitopes exposed to
theT cell (6). On the basis of sequence comparison, Brown et al . (7) have argued
that the overall structures ofhuman and mouseand class I and class II MHC mole-
cules likely share common features, particularly, the presumptive antigen binding
site . This model ofclass IIMHC protein structure is supportedby alarge collection
ofdata examining the response ofT cell hybrids toMHC molecules containing point
mutations . These observations explain in part the phenomenon of MHC-restricted
recognition of antigens (8) . The finding of an electron density in the presumed an-
tigenbinding site ofthe HLA-A2 molecule raises the possibility that this site is always
filled, in theabsence of foreign antigen, with selfpeptides andsuggests that themoiety
recognized by alloreactive T cells is an MHC/peptide complex . Thus, to some de-
gree, thehigh frequency of alloreactive Tcells (9) may be accounted forby the diver-
sity of self-peptide/MHC complexes that constitute the population of alloreactive
molecules (10) .
Our laboratories have previously studied (11, 12) the spontaneous mutation
I-Abm12 (13, 14). Using site-directed mutagenesis of the I-Ab molecule, Ronchese et
al . (11) have examined in detail the effects of the three amino acid substitutions that
constitute the difference between the I-Ab and the I-Abmt2 class II molecules on the
This work was supported by National Institutes of Health grants AI-22259, AR-37070, AI-22295 (E .
Palmer), andAI-00863 (J . Bill) . E. Palmer is a recipient of a Faculty Research Award from theAmer-
ican Cancer Society. Address correspondence to Ed Palmer, Division of Basic Sciences, Department
ofPediatrics, NationalJewish Centerfor Immunology and Respiratory Medicine, 1400Jackson Street,
Denver, CO 80206 .
TheJournal of Experimental Medicine " Volume 170
￿
September 1989
￿
739-750
￿
739740
￿
CONTRIBUTION OF MUTANT AMINO ACIDS TO ALLOANTIGENICITY
MHC-restricted recognition of antigens . In separate experiments, Bill et al. (12) have
generated a panel of 178 I-Ab' 12-reactive T cell hybrids derived from B10 (I-Ab) mice
and have studied the TCR repertoire to this mutant I-A molecule . Here we have
collaborated to study the effects of the individual amino acid substitutions on the
alloantigenicity of the I-Abmt2 molecule. The results are consistent with our previous
conclusions regarding the function and relative importance ofthe three altered residues
and support the Brown et al . (7)model for class II MHC/peptide/TCR interact
These data also provide insight into the role ofTCR/MHC binding and the possible
contributions of MHC-bound peptides to the process of allostimulation .
Materials and Methods
Mice.
￿
C57BL/6 (B6) mice were purchased fromThe Jackson Laboratories, Bar Harbor,
ME . B6.0-H-2 b.12 (bml2) mice were bred in the facilities of National Jewish Center for Im-
munology and Respiratory Medicine, Denver, CO .
T Cell Hybrids.
￿
The characteristics of the hybrids used in this study are given in Table 1 .
The I-A'm12-reactive hybrids and the determination of their TCR variable gene expression
have been described previously (12). Briefly, 5 x 10 5 cell equivalents ofRNA from each hy-
brid was spotted onto multiple nitrocellulose filters that were then hybridized to '2P-labeled
probes specific for Vb 2-17 and Va 1-8, 10, 11, and 13 . All hybridomas were maintained in
complete tumor medium as described (15) .
I-A Transfectants.
￿
Site-directed mutagenesis of the I-Ab b chain to generate all permuta-
tions of the I-Ab and I-Abm12-encoded residues at positions 67, 70, and 71 and transfection
of these constructs along with the I-Ab a chain into mouse L cells have been described pre-
viously (11) . The transfectants were maintained in complete medium plusMXH (mycophenolic
acid, 6 mg/ml ; xanthine, 250 mg/ml ; and hypoxanthine, 15 mg/ml) and were grown on bacterio-
logic petri dishes from which they could be harvested without trypsin .
Flow Cytometry.
￿
For determination of I-A, TCR, and CD4 cell surface expression, 10 5
cells were suspended in buffer (PBS with 2% FCS and 0 .1% sodium azide) and stained with
the appropriate mAbs for 20 min at 37°C in a volume of 100 ml. The cells were washed
with buffer and were then stained with the appropriate fluorescein- or phycocrythrin-conjugated
secondary reagent . After additional washes with buffer, 10,000 cells/sample were analyzed
on an EPICS C flow cytometer. The mAbs used were : M51114 which recognizes I-Ab
I-Abm12 (10, 16) ; H57-597 which recognizes all a/b murine TCRs (17) ; GK1.5 which recog-
nizes murine CD4 (18) ; KJ25 which recognizes TCRs containing Vb3 (19) ; RR4-7 which
recognizesTCRs containingVb6 (20); F23 .1 which recognizesTCRs containingVb8 .1, 8.2,
or 8.3 (21) ; F23 .2 which recognizes TCRs containing Vb8.2 (22) ; KJ16 which recognizes
TCRs containing Vb8 .1 or 8 .2 (23) ; and RR3-15 which recognizes TCRs containing Vbll
(24) . M5/114 wasused as a culture supernatant and the secondary reagent was FITC-conjugated
goat anti-mouse Fc receptor (Rockland, Inc., Gilbertsville, PA) . All other antibodies were
purified from culture supernatants or ascites and biotinylated. The secondary reagent was
phycoerythrin-conjugated streptavidin (Serotec, Oxford, UK) . Values given aremean channel
fluorescence above background . The scale is logarithmic and 85 channels represent a 10-fold
increase.
IL-2 Assay.
￿
IL-2 production was assayed by the ability of supernatants from stimulated
hybrids to support the growth of IL-2-dependent HT -2 cells as described (15) . Briefly, 10 5
T cell hybrids were cocultured with 105 transfectants or 106 spleen cells in 250 ml CTM for
24 h. Twofold dilutions of the resulting supernatant were used to support the growth of 4 x
10 1 HT-2 cells in a volume of 100 ml for 24 h. At the end of this time, wells were examined
for viability of HT-2 cells using phase-contrast microscopy. 5 U of IL-2 are defined as the
minimal amount necessary to maintain the viability of HT-2 cells. HT-2 viability was confirmed
and quantitated by the MTT assay as described (25) . Briefly, 10 ml ofMTT at 5 mg/ml
in PBS was added to each well and incubation was continued at 37°C for 4 h. The plates
were centrifuged for 3 min at 1,000 rpm in a centrifuge (model TJ-6; Beckman Instruments,BILL ET AL.
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TABLE I
TCR and CD4 surface expression was determined by indirect immunofluorescent staining
using H57-597 and GK1 .5 as described in Materials and Methods .
t TCR variable gene expression was determined by hybridization of radiolabeled probes tc
total cellular RNA. Va probes for Va 1-8, 10, 11, 13, and Vß probes for Vß 2-17 were
used. Surface expression ofVß 3, 6, 8, and 11 was confirmed by indirect immunofluores-
cence as described in Materials and Methods . ND indicates lack of hybridization to any of
the radiolabeled Va probes used .
s BW indicates BW5147 was used as the fusion partner . BW/cr is a variant ofBW5147 select-
ed for deletion of the Val gene (26) .
Hybrid
TCR expression*
Percent
positive Mean
CD4 expression*
Percent
positive Mean
TCR variable genest
a ß
Fusions
partner
3 BBM 74 100 145 20 132 2 8 .1 BW
4 BBM 17 99 144 0 5 10 BW
5 BBM 98 93 160 50 133 4 6 BW
6 BBM 51 99 170 47 129 2 8 .1 BW
6 BBM 131 100 196 95 161 4 6 BW
8 BBM 8 100 165 100 172 4 6 BW
8 BBM 10 100 186 97 163 4 11 BW
15 BBM 82 98 157 21 141 5 14 BW
15 BBM 139 97 132 49 133 2 16 BW
16 BBM 30 11}0 154 96 156 3 2 BW
16 BBM 34 99 170 0 4 16 BW
16 BBM 53 55 147 43 156 8 12 BW
16 BBM 100 98 145 13 132 2 6 BW
17 BBM 6 100 148 0 4 14 BW/a-
17 BBM 43 100 184 98 158 3 8 .1 BW
17 BBM 51 100 185 98 157 3 16 BW
17 BBM 64 99 172 30 145 4 15 BW/a -
17 BBM 68 96 164 85 144 8 4 BW/a-
17 BBM 71 99 165 98 156 3 8 .1 BW/a-
17 BBM 82 100 183 100 169 3 8 .1 BW
17 BBM 136 100 177 98 153 2 6 BW/ci-
17 BBM 151 99 195 99 165 3 10 BW/ce-
17 BBM 159 41 120 21 145 8 14 BW/a-
17 BBM 179 87 156 87 141 8 4 BW
17 BBM 190 90 146 92 150 9 10 BW
18 BBM 9 100 181 95 158 8 4 BW/cC
18 BBM 17 100 166 99 166 8 16 BW/cC
18 BBM 19 100 174 100 158 3 6 BW/a-
18 BBM 22 100 187 99 167 ND 3 BW/a-
18 BBM 23 100 171 100 166 5 6 BW/a-
18 BBM 37 100 155 35 135 3 10 BW/a-
18 BBM 49 99 155 94 154 4 6 BW/or
18 BBM 68 100 198 99 161 4 8 .1 BW/a-
18 BBM 78 100 173 64 140 9 8 .3 BW/cC
18 BBM 98 99 176 93 154 3 2 BW/ce-
18 BBM 109 100 183 100 163 5 6 BW/a-
18 BBM 138 100 158 0 3 14 BW/a-
18 BBM 139 100 178 97 155 3 15 BW/a-
18 BBM 142 91 163 64 146 3 14 BW/cC
18 BBM 153 77 147 0 4 14 BW/cC
18 BBM 160 100 157 100 174 2 16 BW/a-742
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Inc., Fullerton, CA). The medium wasdiscarded and the cell pellet wasredissolved in 7050
(vol/vol) isopropanol, 2% (vol/vol) 1 N HCI. ODsso was then read on an ELISA reader, and
IL-2 values were determined by comparison with a standard curve. Each hybrid was tested
on at least three occasions and the values given are from representative experiments.
Results
Cell Hybridomas.
￿
We have previously generated a panel of 178 I-AbmU-specific
T cell hybrids derived from C57BL/10 mice (12). Table I lists 41 of these hybrids
that were selected for the present study. To correlate TCR a and b variable gene
expression with fine specificity, hybrids were chosen that express only one Va and
one Vb mRNA. All hybrids express surface TCR as determined by indirect im-
munofluorescent staining with the panTCR-reactive mAb 597 (17). The majority
of hybrids were >90% positive at the time of analysis and the expression of TCR,
as assessed by themean channelof thepositive cells, differed by up to 8-fold (a differ-
ence of 85 channels corresponds to adifference of 10-fold). Indirect immunofluores-
cent staining forCD4 surface expression similarly demonstrated that the majority
of hybrids express this accessory molecule; however, with 14 hybrids, only 50°70 or
less of the TCR+ cells were also CD4+, while five hybrids showed no detectable CD4
on the cell surface. TCR V gene expression by these hybrids was previously deter-
minedby hybridization ofradiolabeled V-specific probes to total cellular RNA. One
hybrid, 18BBM22, most likely expresses a Va for which we did not have a probe.
TCRVii 3, 6, 8, and 11 surface expression was confirmed by indirect immunofluores-
cent staining with specific mAbs. V08 family members were determined by com-
parison of staining with F23.1, F23.2, and KJ16 as described (22). Also listed is the
fusion partner used to generate the hybrid. BW/a- has deleted the Vat gene ex-
pressed in BW5147 (23).
Transfected Fibroblastpresenting Cells.
￿
As the I-Abm12 mutation involves only three
amino acid substitutions in the I-Ab a chain (Ile-Phe61 , Arg-Gln", and Thr-
Lys"), one can examine the importance of individual amino acid substitutions by
changing the residues one or two at a time, resulting in eight permutations of the
I-Ablbm12a chain. Site-directed mutagenesis of thea chain of the I-A' molecule and
transfection of the resulting constructs along with the I-Ab a chain into mouse L
cells has been previously described(11). Forreference, phenotypic data are reproduced
in Table II along with indirect immunofluorescent staining data ofthe transfectants
using the mAb M5/114, which does not discriminate between I-Ab and I-Abm12 (11).
Values given are the mean channel fluorescence above background determined on
two occasions 1 mo apart during the course of this study. On both occasions virtu-
ally 100% of the cells were positive and the intensity of staining was relatively con-
stant. With theexception of FT 6.7, none of the transfectants differed among them-
selves by more than twofold in their level of I-A expression. Table III shows that
all transfectants containing an I-Abm12-derived residue at position 67, 70, or 71 could
stimulate at least one I-Abm12-reactive T cell hybrid. A panel of six I-Ab (autoreac-
tive) T cell hybrids were used to confirm presentation of I-Ab by FT7.1 and B6
spleen (data not shown).
Reactivity of I-A'- andIAlm12-speck TCell Hybrids to Transfected Fibroblasts Expressing
the Partially or Fully Reconstituted IAbm12 Mutation.
￿
Table III (A-F) shows the IL-2BILL ET AL .
￿
743
TABLE II
' Numbers refer to residue position in the mature Ag polypeptide chain .
$ Cells were stained with M5/114 on 2 occasions as described in the Results
section .
s b, amino acid from Ab; bm, amino acid from Abm~12 .
production of I-Abm12-specific T cell hybrids in response to the panel of transfected
fibroblasts that express all possible permutations of the I-Ab or I-Abm12 amino acids
at residues 67, 70, and 71 of the I-A ß chain . Several distinct patterns of reactivity
are apparent . Table III A shows six hybrids that produce IL-2 when stimulated by
spleen cells from B6.C-H-2bm12 but that fail to produce IL-2 in response to the
I-Abm12-bearing fibroblast FT7.2 . The remaining hybrids in Table III, B-F, are all
capable of responding to I-Abm12 on fibroblasts, though they differ in their require-
ments for specific I-Abm12 residues . The 12 hybrids in Table III B require that all
three residues of the I-A ß chain be derived from the I-Abm12 sequence . Some hy-
brids respond with approximately equal strength to either spleen cells or fibroblasts
while others demonstrate a clear preference for one or the other. Table III C shows
six hybrids that are dependent only on the presence ofbm12 residues at positions
67 and 70 . Hybrid 15BBMI39 can respond weakly when only residue 70 is mutated
and hybrid 17BBM68 can respond weakly if either residue 67 or 70 is mutated, but
both respond more vigorously when both residues are bm12 derived . Table IIID
shows four hybrids that require thebm12 phenotype only at position 70 and respond
to all four transfected fibroblasts that express this mutated residue either alone or
in combinationwith altered residues 67 and/or 71 . The nine hybrids shown in Table
III E require bm12-derived residues at positions 70 and 71 . Finally, the four hybrids
shown in Table III F display unusual reactivity patterns. For example, 18BBM142
reacts with FT6.3 (bm67,b",b 71) and FT7.2 (bin67,bm70 bm71) transfectants but not
with the (bin67 ,b70 bM71) or (bin67,bM70,b71) transfectants . Thus, the bm12 residue
at position 67 can be recognized by this hybrid but not in all contexts . Hybrid
17BBMI36 reacts with FT6.3 (bm67 ,b70 b71) or with FT6.8 (b67 bM70,bM7'), but
more vigorously with FT7 .2 (bm67,bm70 bM 7 '). The hybridoma 17BBM71 is most
dependent on the presence of the bm12-derived glutamine at position 70 as it reacts
with the FT6.4 (b67,bM70'b71) ' FT6.5 (b67,bm70,bM71 ), and FT7.2 (bm67,bm70,bm 71 )
transfectants. Surprisingly, this hybrid is not stimulated with the FT7.7
(bm67,bM70,b 71 ) transfectant. Finally, 4BBM17 inexplicably reacts much more
vigorously with the FT6.7 (bm67,b70 bM71) transfectant than with the transfectant
that carries the complete bm12 mutation .
Transfectant 67
Sequence"
70 71
I-A surface staining
(mean channel fluorescence)t
FT 6.3 bms b b 140/144
FT 6.4 b bm b 162/134
FT 6.5 b b bm 127/138
FT 6.7 bm b bm 98/114
FT 6.8 b bm bra 147/131
FT 7.7 bm bm b 135/133
FT 7.1 b b b 120/134
FT 7 .2 bm bm bm 145/124744
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Discussion
The three amino acid substitutions, Ile-Phe62 , Arg-Gln2°, and Thr-Lys21 ,
which distinguish the0 chain of I-Ab from that of I-Abm12 , were originally detected
by the ability ofmice that differed at only this locus to reciprocally reject skin grafts.
It has also been shown that these mice differ in their ability to present and respond
to exogenous antigen (27, 28). Understanding in molecular terms howthree amino
acid substitutions so dramatically perturb the T cell repertoire ofthese mice should
provide important information about the relationship betweenMHC molecule struc-
ture and function regardingboth thymic selection andantigen presentation. Although
the bm12 mutation is the sole spontaneous class II mutation discovered so far (vs.
20 spontaneous class I mutations), it seems likely that the mutation is biologically
effective because it involves residues that are critical to class II MHC function. Se-
quence comparisons of the mutated I-A'm120 chain with those of other I-A0 chains
show the mutated residues to lie in the third hypervariable region. We have previ-
ously demonstrated the importance of the hypervariable regions to antigen presen-
tation and allostimulation usingexon-shuffling techniques to localize relevant struc-
tures to the NH2-terminal 97 residues (29-31). Others have also demonstrated the
importance of this region usingin vitro mutagenesisto change specific amino acids
in the hypervariable regions including residues 65, 66, and 67 of I-Ab, a change
that overlaps with the bm12 mutation (32). In previous experiments (11), we have
investigated the relative contribution of each of the three amino acid substitutions
that constitute the bm12 mutation to the observed serologic differences and to the
changes in antigen presentation. mAbs that distinguish I-Ab from I-Abm12 are pri-
marily or solely dependent on the change at residue 70 (Arg-"Gin), implying that
this residue is uniquely accessible to antibody (and presumably to TCRs). In the
same experiments, we also demonstrated that all three residues were important to
antigen presentation to T cells, suggesting that amino acids67 and 71 affected quan-
titative and/or qualitative aspects of peptide binding to Ia. Using the existing struc-
ture/function data and sequence similarity with the human class I molecule HLA-
A2 for which the crystal structure has been solved, Brown et al. have proposed a
physical model for class II molecules. Consistent with the observed importance of
the bm12 mutation, this model places the mutated, bm12 residues on one of the he-
lical portions of the molecule that form the presumed antigenbindingsite. According
to the model, residues 67 and 71 point down into the binding site, and thus, are
ideally suited to affect binding of antigen, i.e., peptides. Residue 70 points up and
away from the helix and thus is accessible to responding Tcells and their receptors.
Thus, both structural modeling and functional results of experimental manipula-
tion of the I-Ab molecule yield a congruent picture of the probable roles of residues
067, 70, and 71 in peptide or TCR binding.
In the present set of experiments, we have extended our observations to a large
panel of previously established (12) alloreactive T cell hybridomas, specific for I-
Abm12 . We examined the response of 41 I-Abm12-specific hybridomas (see Table I)
to a panel of eight fibroblast cell lines transfected with constructs encoding various
permutations of the I-Ab/bm12 molecule (see Table 11). Surprisingly, the reactivities
of these hybrids segregated into a small number of patterns. Six hybrids (see Table
III A) do not respond to the I-Abm12 molecule expressed on the surface of L cells
but do respond when I-A"12 is expressed on the surface of splenocytes. This is dis-BILL ET AL.
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cussed further below. 12 of the 35 hybrids that can recognize I-Abm12 on transfected
fibroblasts require the "complete" I-Abm12 phenotype (I-Abm12-encoded aminoacids
at positions 67, 70, and 71). Of the 23 hybrids that can be stimulated by less than
the "full" bm12 mutation, four hybrids (see Table III D) are capable of responding
when position 70 represents the only I-Abm12-encoded amino acid, six hybrids (see
Table III C) require the presence of I-Ab-12-encoded amino acids at positions 67
and 70, and nine hybrids (see Table III E) require I-Abm12-encoded residues at po-
sitions 70 and 71 for the production of IL-2. Finally, four hybrids (see Table III
F) have reactivities that are complex and noteasily categorized. These hybridsgenerally
recognize a specific I-Abm12 residue but not in all contexts. Interestingly, the hybrid-
omas in each category do not express a particular set of Vac or VR gene segments.
Thus, even when these alloreactive hybrids are grouped by their fine specificity, no
simple pattern ofVa or V0 expression emerges. Apparently, alloreactive T cells with
the same fine specificity express a diverse array of V gene segments.
The most striking feature of our data is the importance of the residue at position
70. Only 4 of the 35 hybrids that are capable of responding to the I-Abm12 molecule
expressed on the surface of L cells can tolerate the loss of the I-Abm12-encoded mu-
tant residue at position 70 and two (17BBM68 and 17BBM136) of these are 10-fold
less reactive when this amino acid is I-Ab derived. It is remarkable that asingle sub-
stitution at this position should interfere with the majority of I-Abm12-reactive T cell
hybrids, and this finding strongly suggests that this residue directly interacts with
TCRs. Such an interaction would be consistent with the proposed model of class
II structure that places the Gln70 of the I-Am12 R chain on one of the a-helical
regions pointing up and away from the presumed Ag binding site, i.e., toward the
T cell. While we favor the interpretation that Gln70 is directly involved in binding
to alloreactive TCRs, it is also possible that this altered residue sterically inhibits
a separate TCRMHC interaction or a peptide-MHC interaction.
The large majority (28 of 35) of I-Abm12-reactive hybrids that recognize I-Abm12
on transfected fibroblasts show an absolute requirement for I-Abm12_encoded amino
acids at position 67 and/or 71 as well. Since the amino acids at these two positions
are thought to point down and into the peptidebinding groove, their effects on allo-
recognition may be indirect. One obvious explanation is that the actual ligand rec-
ognized by alloreactive T cells is a self-peptide/MHC complex and that the amino
acids at positions 67 and 71 affect what peptides can actually be bound by the
I-Abm12 glycoprotein. Permuted I-Abm12 molecules may not bind the same proteo-
lytic fragments as the "complete" I-Abm12 molecule, accounting for the observed pat-
terns of reactivity. Further support for this idea comes from the finding that six of
the I-Abml2-specific hybrids (Table III A) do not respond to the "complete" I-Abm12
molecule expressed on the surface of L cells but do respond when this molecule is
expressed on the surface of splenocytes. Given the presence of identical I-A'12 genes
in the two cell types, it is possible that fibroblasts lack a particular proteolytic frag-
ment that contributes to the peptide/MHC ligand; this potentially explains the be-
havior of the hybridomas listed in Table III A. This phenomenon has been observed
for I-E-reactive T cell hybrids that respond to I-E expressed on splenocytes but not
to I-E expressed on fibroblasts (33). Conversely, we have identified two hybrids
(17BBM43 and 18BBM22) that weakly recognize I-Abm12 expressed on spleen cells
but secrete 5-10-fold more IL-2 when stimulated with I-Abm12-transfected fibro-748
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blasts. Fibroblasts may express a peptide that contributes to the ligand recognized
bythe TCRson these twohybridomas that is lacking orpoorly expressed in spleno-
cytes. Anothermechanism by which themutations at positions 67 and 71 may have
theireffect is that while they still allowbinding ofcertain peptides, they
altered conformation on the resultant peptide-MHC complex and thus change the
epitope available to T cells.
From these experiments, we have been able to determine therelative contribution
ofthe individual amino acid replacements towards the alloantigenicity ofthe I-Abrn12
molecule. Clearly, the amino acid at position 70 has the most pronounced effect on
the aloantigenicity of I-Abm]2 in that the reversion of Gln7°-Arg7O interferes with
allorecognition by 33 of 35 I-Abm12_reactive hybrids. This amino acid most likely
participates in a direct interaction with the majority o£I-Abm12-specificTCRs. Our
data also provide experimental support for the Brown et al. (7) model of class II
MHC structure, whichpredicts that theaminoacidat position 70ofthe I-A 0 chain
points up andaway fromthe surface ofthe MHC molecule and is accessible to rele-
vant TCRs. Reversion o£the amino acidsat positions 67 and 71 affects asignificant
but smaller fraction ofI-Abm12-reactive Tcells. The effects ofsubstitutions at these
positions maybe mediated through theeffects ofbinding ofself-peptides on the an-
tigen binding site.
Summary
The I-Abm12 mutation has been used extensively to study the relationship between
structure and function of murine class II major histocompatibility molecules.
I-A'12 differs from I-A' by three amino acid replacements in the A# chain, and
the proposed structural model o£the I-Ab"2 molecule places these three amino acid
substitutions alongoneofthea-helices where theymay affect both antigenandTCR
binding. Two ofthe substitutions, Ile-Phe67 and Thr-Lys", are thought to point
into thebinding site, whereas the third substitution, Arg-Gln7°, is thought to point
up and hence, be available for binding to the TCR. These predicted orientations
are consistent with serologic analysis ofthe bm12 molecule, which demonstrates that
residue 70 is uniquely accessible to mAbs distinguishing I-Ab from I-Abm'2. In this
study we have determined the influence of each of these amino acid substitutions
on the ability ofthe resulting molecules to stimulate a panel ofI-AbmI2 (allo) reac-
tive Tcell hybridomas. Our experiments indicate that reversion ofthe amino acid
at position 70 from Gln (I-A112) to Arg (I-Ab) interferes with allorecognition by
33 of35 I-Abm'2-reactive hybridomas. On the otherhand, many hybrids can tolerate
amino acid substitutions at positions 67 or 71. Single amino acid substi
position 67, 70, or 71 are recognized by only a minority ofI-A'12-specific by
andusually thereactivity isgreatlydiminished. Thesedata are most consistent with
the ideathat the amino acid at position 70 directly interacts with the TCR during
allorecognition. The additional effects ofresidues 67 and 71 are consistent with a
contribution by bound peptide to the allorecognition process.
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